Researchers at the National Cancer Institute (NCI) have developed a monoclonal antibody against ataxia telangiectasia-mutated and Rad3-related (ATR) kinase phosphorylated at threonine 1989. The antibody can be used for pharmacodynamic assays to quantify drug action on the ATR target.
Researchers at the National Cancer Institute (NCI) developed a method of producing larger populations of minimally-differentiated, persistent T-cells, which is critical for successful treatments, using p38 mitogen-activated protein kinase (MAPK) inhibitors. NCI seeks licensing and/or co-development research collaborations to further develop, evaluate, and/or commercialize this new method.
Investigators from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) have identified five autophagy-inhibiting compounds (WX8 family) through a high-throughput screening. The NICHD seeks licensees and/or co-development partners for methods to treat cancer by administering these autophagy-inhibiting compounds.
National Cancer Institute (NCI) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seek licensees for a technology involving the preparation and use of personalized tumor vaccines for cancer immunotherapy employing a therapeutic strategy called MBTA. MBTA consists of vaccinations with irradiated tumor cells pulsed with phagocytic agonists (Mannan-BAM, a polysaccharide derivative of mannan), TLR (Toll-like receptor) ligands, and agonistic Anti-CD40-monoclonal antibody.
Increased cyclin-dependent kinase 5 (CDK5) activity has recently emerged as a contributor to cancer progression. Researchers at the National Cancer Institute (NCI) and at the National Institute of Neurological Disorders and Stroke (NINDS) have shown that TP5, a small peptide inhibitor of CDK5 modified to facilitate passage through the blood brain barrier (BBB), has potential therapeutic benefit in glioblastoma (GBM) and colorectal carcinoma (CRC). NCI is seeking parties interested in co-developing and/or licensing TP5 for its use in the treatment of cancers with aberrant CDK5 expression as a mono-therapy or in an adjuvant setting with current standard-of-care.
The Protein Expression Laboratory at the National Cancer Institute in Frederick, MD is seeking statements of capability or interest from parties interested in collaborative research to further develop a platform technology for the targeted intra-cellular delivery of proteins using virus-like particles (VLPs).
The National Institutes of Health Clinical Center (NIH CC) and the National Cancer Institute (NCI) are seeking parties interested in licensing a multi-foci sonication approach combined with a mild hyperthermia heating algorithm and implemented on a clinical Magnetic Resonance-Guided High-Intensity Focused Ultrasound (MR-HIFU) platform.
Adoptive cell therapy uses cancer reactive T-cells to effectively treat cancer patients. Producing many persistent T-cells is critical for successful treatments. Researchers at the NCI seek licensing and/or co-development research collaborations for a novel method of producing effective T-cell populations using Akt inhibitors.
Researchers at the National Cancer Institute (NCI) developed five high-affinity, fully human monoclonal antibodies targeting FLT3. Chimeric antigen receptors (CARs) have also been constructed based on the antibodies identified and tested in animal models of acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL).
Researchers at the National Cancer Institute (NCI) have developed a new format for expressing Chimeric Antigen Receptors (CARs) that is available for licensing and co-development. The inventors found that there was an increased therapeutic effect when using their proprietary (anti-glypican 3 [GPC3]) hYP7 antibody in this format. The novel technology is useful for improving CAR therapies to treat a range of cancers.
Somatic mutations can alter the sensitivity of tumors to T-cell mediated immunotherapy. Identifying genes that positively regulate the sensitivity of cancer cells to T-cell mediated clearance is key for effective treatment in cancer patients. Researchers at the National Cancer Institute (NCI) have identified a panel of genes which are useful in predicting a patient’s response to immunotherapy. NCI seeks partners to co-develop or license the technology toward commercialization.
The National Cancer Institute’s Laboratory of Human Carcinogenesis seeks parties to license or co-develop a method of predicting the prognosis of a patient diagnosed with hepatocellular carcinoma (HCC) or breast cancer by detecting expression of one or more cancer-associated genes, and a method of identifying an agent for use in treating HCC.
Researchers at the National Cancer Institute (NCI) have isolated two Glypican-1- (GPC1)- specific antibodies: the mouse monoclonal antibody HM2 that binds the C-lobe of GPC1 close to the cell surface, and the camel single domain antibody D4. The D4 single domain antibody (also called ‘nanobody’) has a high affinity for GPC1-positive tumor cells from both human and mouse origins. The NCI seeks licensing and/or co-development research collaborations to advance the development and commercialization of these antibodies.